JP2013521314A - 癌の処置のためのチゲサイクリンの使用 - Google Patents

癌の処置のためのチゲサイクリンの使用 Download PDF

Info

Publication number
JP2013521314A
JP2013521314A JP2012556354A JP2012556354A JP2013521314A JP 2013521314 A JP2013521314 A JP 2013521314A JP 2012556354 A JP2012556354 A JP 2012556354A JP 2012556354 A JP2012556354 A JP 2012556354A JP 2013521314 A JP2013521314 A JP 2013521314A
Authority
JP
Japan
Prior art keywords
cancer
cells
mitochondrial
tigecycline
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012556354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013521314A5 (enExample
Inventor
アーロン、ディー.シメール
マルコ、スクルティク
Original Assignee
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2013521314A publication Critical patent/JP2013521314A/ja
Publication of JP2013521314A5 publication Critical patent/JP2013521314A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/142Toxicological screening, e.g. expression profiles which identify toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
JP2012556354A 2010-03-10 2011-03-10 癌の処置のためのチゲサイクリンの使用 Withdrawn JP2013521314A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31241010P 2010-03-10 2010-03-10
US61/312,410 2010-03-10
PCT/CA2011/000258 WO2011109899A1 (en) 2010-03-10 2011-03-10 Use of tigecycline for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2013521314A true JP2013521314A (ja) 2013-06-10
JP2013521314A5 JP2013521314A5 (enExample) 2014-04-24

Family

ID=44562767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012556354A Withdrawn JP2013521314A (ja) 2010-03-10 2011-03-10 癌の処置のためのチゲサイクリンの使用

Country Status (6)

Country Link
US (1) US20120329761A1 (enExample)
EP (1) EP2544692A4 (enExample)
JP (1) JP2013521314A (enExample)
CN (1) CN102821769A (enExample)
CA (1) CA2790240A1 (enExample)
WO (1) WO2011109899A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2842228A1 (en) * 2011-07-15 2013-01-24 University Health Network Combination treatment for cancer
WO2014029016A1 (en) * 2012-08-24 2014-02-27 University Health Network Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer
CN108329312B (zh) 2012-08-31 2021-12-31 四相制药公司 四环素化合物
EP3327144B1 (en) 2013-02-25 2020-03-25 Novartis AG Novel androgen receptor mutation
CN103142624A (zh) * 2013-03-01 2013-06-12 西南大学 抗生素替加环素在制备抗癌药物中的应用
WO2014138338A1 (en) * 2013-03-06 2014-09-12 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
CN110167560B (zh) * 2016-08-30 2023-08-18 四相制药公司 四环素化合物和治疗方法
HUE066360T2 (hu) 2016-10-19 2024-07-28 Tetraphase Pharmaceuticals Inc Eravaciklin kristályformái
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CN109331026A (zh) * 2018-04-21 2019-02-15 温州医科大学附属第医院 替加环素在制备抗多发性骨髓瘤药物中的应用
CA3102264A1 (en) * 2018-06-19 2019-12-26 Lunella Biotech, Inc. "energetic" cancer stem cells (e-cscs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
WO2001035096A2 (en) * 1999-11-10 2001-05-17 Mitokor Diseases associated with altered mitochondrial function
WO2002038759A2 (en) * 2000-11-10 2002-05-16 Mitotech Ab Method for inducing apoptiosis
JP2005505588A (ja) * 2001-10-05 2005-02-24 テトラジェネックス ファーマスーティカルズ インク テトラサイクリン誘導体、及びそれを使用する方法
WO2004064728A2 (en) * 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
US20050148553A1 (en) * 2003-09-05 2005-07-07 Testa Raymond T. Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis
AR057032A1 (es) * 2005-05-27 2007-11-14 Wyeth Corp Tigeciclina y metodos de preparacion

Also Published As

Publication number Publication date
CN102821769A (zh) 2012-12-12
US20120329761A1 (en) 2012-12-27
WO2011109899A1 (en) 2011-09-15
CA2790240A1 (en) 2011-09-15
EP2544692A1 (en) 2013-01-16
EP2544692A4 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
JP2013521314A (ja) 癌の処置のためのチゲサイクリンの使用
AU2013342267B2 (en) Small molecule inhibitors of MALT1
JP5688288B2 (ja) がんの処置のための相乗的な医薬の組合せ
JP6132833B2 (ja) 抗癌療法としての正常細胞および腫瘍細胞の小分子trail遺伝子誘導
US9771625B2 (en) Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer
US20210186993A1 (en) Combination therapies targeting mitochondria for cancer therapy
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
JP2014514326A5 (enExample)
EP2880014A1 (en) Compounds for the treatment of mtor pathway related diseases
CN102791260A (zh) 低氧诱导因子抑制剂的用途
EP3062790A1 (en) Pharmaceutical combinations for the treatment of cancer
JP2009543874A (ja) チアゾリジノン誘導体
US20140221301A1 (en) Combination treatment for cancer
WO2014029016A1 (en) Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer
US11583509B2 (en) Compound for treating cancer and diabetes
US20220016118A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
EP3405194B1 (en) A temporary inhibitor of p53 in combination with an anticancer agent for use in the preventing or reducing cancer relapse
US20230201168A1 (en) New therapy for the treatment of tumors
JP2024506847A (ja) がんを処置および改善するための方法
WO2019168177A1 (ja) 癌の予防または治療剤
WO2024023279A1 (en) Cancer combination therapy including a bcl-2 inhibitor
Kokkinis et al. Liposomal Encapsulated Curcumin Attenuates Lung Cancer Proliferation, Migration and Apoptosis
NZ622752A (en) Romidepsin and 5 - azacitidine for use in treating lymphoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140310

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20141008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141008